Japan’s Daiichi Sankyo Co is in talks with several companies to sell its wholly-owned over-the-counter (OTC) drug unit, with the final price likely to reach around 100 billion yen ($900 million), Nikkei Business...
Merck buys Peloton to expand its kidney cancer treatment portfolio
U.S. drugmaker Merck & Co Inc on Tuesday agreed to buy Peloton Therapeutics Inc for $1.05 billion in cash, gaining access to the privately held company’s lead kidney cancer drug candidate. The acquisition can...
Orchid Pharma says closer to resolution as RP has received three plans
Orchid Pharma Ltd is one step closer to finalising its second attempt to find a resolution plan under the Corporate Insolvency Resolution Process (CIRP) it initiated earlier, as the Resolution Professional (RP) received...
AstraZeneca moves US court against Aurobindo Pharma on generic Daliresp
Pharma major AstraZeneca has filed a petition in a US court, alleging that Aurobindo Pharma is attempting to come out with the generic version of its patented drug Daliresp (Roflumilast Tablet 500 mcg). In a petition...
Takeda sells dry eye drug to Novartis to help cut debt
Takeda Pharmaceutical Co Ltd agreed to sell its dry eye drug to Swiss drugmaker Novartis AG for $3.4 billion and potential milestone payments of up to $1.9 billion, in the first divestment since its takeover of...
Carlyle-Zydus and Advent join race to acquire Bharat Serums and Vaccines Ltd
A consortium of Carlyle and Zydus Cadila is competing with private equity group Advent International to acquire Mumbai-based bio-pharmaceutical company Bharat Serums and Vaccines Ltd. (BSV). The two have submitted non...
Government invites initial bids for strategic sale of IMPCL
The government has invited initial bids for selling its entire stake in Indian Medicines Pharmaceutical Corporation Ltd (IMPCL). IMPCL is engaged in manufacture and supply of ‘ayurvedic’ and...
General Atlantic to invest $100 million in Rubicon
Private equity firm General Atlantic will invest $100 million in Rubicon Research Pvt. Ltd, the pharmaceutical product development company in which it acquired a controlling stake last week. Rubicon Research said in a...
AstraZeneca in cancer drug deal that could pay Daiichi Sankyo up to $6.9 billion
AstraZeneca Plc and Daiichi Sankyo Co Ltd signed a deal to develop and sell Daiichi’s cancer drug trastuzumab deruxtecan that could see the British drugmaker pay as much as $6.9 billion to its Japanese partner. The news...
NCLT reads insolvency rules at Orchid Pharma’s promoter group firm
The insolvency resolution procedure will be applied on Orchid Healthcare, a promoter group company of Chennai-based Orchid Pharma, which is already under this procedure. The order, from the bench of the National Company...
Merck KGaA goes hostile in $5.9 billion Versum takeover battle
German pharma group Merck KGaA launched a hostile $5.9 billion all-cash takeover offer for Versum Materials on Tuesday to boost its presence in the semiconductor materials market and sideline a rival bidder. Versum, the...
PharmEasy in early funding talks with SoftBank at double its valuation
Japan’s SoftBank Group Corp. is in early talks to invest close to $100 million in online medicine startup PharmEasy, three people aware of the matter said. PharmEasy is seeking a valuation of about $400 million in the...
